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Abstract: Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by ฀-galactosidase A
(฀-Gal A) deficiency. The progressive accumulation of globotriaosylceramide results in life-threatening
complications, including renal, cardiac, and cerebrovascular diseases. The pharmacological chaperone
migalastat was recently approved as an alternative to enzyme replacement therapy in patients with
amenable mutations. In this paper we investigate the proportion of amenable mutations, related to
phenotype, in a population of adult patients with FD in Switzerland. This study included 170 adult
patients (n = 64 males) from 46 independent pedigrees with 39 different identified mutations over the
last 59 years. Overall, 68% had the classic phenotype and 48% fulfilled the current amenability criteria.
Migalastat was stopped in 2/11 (18%) patients: the only male classic patient, because of lack of efficacy
based on lyso-Gb3 levels, and 1 patient with a benign variant. In males, the achieved enzyme activities in
peripheral leucocytes under migalastat treatment differed from the activities in HEK-cells after incubation
with migalastat (eg, 33% in PL vs 41% HEK-cells for p.F113 L; 43% in leucocytes vs 36% in HEK-cells
for p.N215S, 24-30% in leucocytes vs 96% in HEK-cells for S238 N). In this national cohort, we found a
relatively high proportion of patients with amenable GLA mutations, which, however, had heterogeneous
extent of amenability: the higher the residual ฀-Gal A activity, the higher the chaperone effect. Further
studies are required to investigate the long-term benefits of migalastat therapy depending on the achieved
enzyme activities in different amenable mutations. This article is protected by copyright. All rights
reserved.
DOI: https://doi.org/10.1002/jimd.12167





Nowak, Albina; Huynh-Do, Uyen; Krayenbuehl, Pierre-Alexandre; Beuschlein, Felix; Schiffmann, Raphael;
Barbey, Frédéric (2020). Fabry disease genotype, phenotype and migalastat amenability: insights from




Fabry disease genotype, phenotype and migalastat amenability: insights from a 




, Uyen Huynh-Do 
3
, Pierre-Alexandre Krayenbuehl 
4









Swiss Foundation of Fabry Disease 
 
1
 Department of Endocrinology and Clinical Nutrition, University Hospital Zurich and 
University of Zurich, Raemistrasse 100, 8091 Zurich, Switzerland, albina.nowak@usz.ch  
2
 Department of Internal Medicine, Psychiatry University Hospital Zurich, Lenggstrasse 31, 
8032 Zurich, Switzerland 
3
 Department of Nephrology and Hypertension, University Hospital Bern, Freiburgstrasse 15, 
3010 Bern, Switzerland, uyen.huynh-do@insel.ch 
4
 Department of Internal Medicine, Linth Hospital, Gasterstrasse 25, 8730 Uznach, 
Switzerland, pierre-alexandre.krayenbuehl@spital-linth.ch 
5 
Institute of Metabolic Disease, Baylor Scott & White Research Institute, 3812 Elm Street. 
Dallas, Texas 75226, USA, raphael.schiffmann@BSWHealth.org 
6
 Division of Genetic Medicine, Lausanne University Hospital and University of Lausanne, 




Dr. Albina Nowak 
Department of Endocrinology and Clinical Nutrition  
University Hospital Zurich 
Rämistrasse 100  
CH-8091 Zürich 














This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process which may lead to 





Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by -galactosidase A 
(-Gal A) deficiency. The progressive accumulation of globotriaosylceramide results in life-
threatening complications, including renal, cardiac, and cerebrovascular diseases. The 
pharmacological chaperone migalastat was recently approved as an alternative to enzyme 
replacement therapy in patients with amenable mutations.  
In this paper we investigate the proportion of amenable mutations, related to phenotype, in a 
population of adult patients with FD in Switzerland.   
This study included 170 adult patients (n=64 males) from 46 independent pedigrees with 39 
different identified mutations over the last 59 years. Overall, 68% had the classic phenotype 
and 48% fulfilled the current amenability criteria. Migalastat was stopped in 2/11 (18%) 
patients: the only male classic patient, because of lack of efficacy based on lyso-Gb3 levels, 
and 1 patient with a benign variant. 
In males, the achieved enzyme activities in peripheral leucocytes under migalastat treatment 
differed from the activities in HEK-cells after incubation with migalastat (e.g. 33% in PL vs 
41% HEK-cells for p.F113L; 43% in leucocytes vs 36% in HEK-cells for p.N215S, 24-30% 
in leucocytes vs 96% in HEK-cells for S238N).  
In this national cohort, we found a relatively high proportion of patients with amenable GLA 
mutations, which, however, had heterogeneous extent of amenability: the higher the residual 
-Gal A activity, the higher the chaperone effect. Further studies are required to investigate 
the long-term benefits of migalastat therapy depending on the achieved enzyme activities in 
different amenable mutations.   
  












Take-home message  
In this national cohort, we found a high proportion of patients with amenable GLA mutations, 
which had heterogeneous extent of amenability: the higher the residual -Gal A activity, the 
higher was the chaperone effect.  
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Fabry disease (FD) (OMIM#301500) is a rare X-linked inborn error of glycosphingolipid 
catabolism resulting from the deficient activity of the lysosomal hydrolase -Galactosidase A 
(EC 3.2.1.22; -Gal A) (Desnick et al 2001). The enzymatic defect causes progressive 
accumulation of globotrioasylceramide (GL-3) and related glycosphingolipids with terminal 
-linked galactosyl moieties in plasma and in cells.   
There are two major phenotypes, classic and late-onset (Desnick et al 2001; Arends et al 
2016; Nowak et al 2016). In males, the classic phenotype is the most severe due to very low 
(<3%) residual -Gal A activity, with early symptoms including acroparesthesias, 
angiokeratoma, corneal opacities and hypohidrosis. The progressive deposition of GL-3 
gradually leads to cardiomyopathy, chronic nephropathy, and premature strokes (Schiffmann 
et al 2009). In heterozygous females, -Gal A activity can range from low to normal due to 
random X-chromosomal inactivation (Echevarria et al 2016). Females typically have milder 
symptoms, but can have very heterogeneous phenotypes (Desnick et al 2001).  
The standard treatment for FD is recombinant enzyme replacement therapy (ERT), 
administered intravenously every other week, with the potential disadvantage of requiring a 
long-term biweekly infusion (Eng et al 2001; Schiffmann et al 2001; Germain et al 2015). 
Recently, the first oral therapy with migalastat, a pharmacological chaperone, has been 
approved by the EMA and FDA (Germain et al 2016). However, migalastat is only indicated 
in a subgroup of patients who have amenable pathogenic GLA mutations.  
Attempts have been undertaken to estimate the proportion of mutations amenable to 
migalastat in a Fabry population. Testing for single mutations in patients who participated in 
phases I-III migalastat studies for cellular response to migalastat showed that ~ 45% of 
mutations were amenable (Benjamin et al 2017). So far, no estimates of real-life proportions 












of patients with amenable mutations in a given country have been published. Moreover, no 
study has analyzed the baseline activity and degree of amenability in relation to clinical 
phenotype in a patient population. We therefore explored the mutational landscape in the 
whole country for amenability by phenotypes and for the dynamics of new FD diagnoses by 
phenotype and amenability. Such analyses were possible because all patients who have ever 
been diagnosed with FD in Switzerland were genotyped, phenotyped, treated and followed up 
at three specialized Fabry Centres. The Swiss experience could be extrapolated to other 

















This is a retrospective analysis of a prospective, multi-centre cohort in Switzerland. The study 
was conducted in accordance with the principles of the Helsinki Declaration. Each author has 
read and approved the manuscript. 
Study participants 
All patients in Switzerland who were ever diagnosed to have FD and had a confirmed 
pathogenic GLA-mutation have been included in this analysis. Consecutive FD patients were 
systematically registered and routinely followed-up through their lifetime, at least annually, at 
one of the three tertiary care hospitals – University Hospitals Zürich, Lausanne and Bern. If 
patients died outside of the Fabry Centres, the date of death was obtained by the general 
practitioner, the family or the nurse administering ERT in the home care setting. For the 
present analyses, all demographic, clinical, biomolecular information and survival status until 
December 31, 2018 arise from the patients' medical records.  
α-Gal A activities were originally determined at the time of diagnosis in males in the same 
laboratory (Universitäts-Kinderspital Zürich). In 6 patients on migalastat, α-Gal A activities 
were additionally measured after 1-3 months of migalastat initiation and subsequently re-
measured every 3-6 months; in 5 patients α-Gal A activities were measured 1-2 times after 
migalastat initiation. The α-Gal A sampling was random and not related to migalastat 
administration. 
 
These results were averaged for each patient, to determine his/her α-Gal A activity on 
migalastat treatment. Lyso-Gb3 levels in dried blood spots (DBS) were determined before and 
6-18 months after therapy initiation with migalastat.  
Phenotyping and amenability categorization   












The phenotype was classified based on genotype and residual α-Gal A activity in males 
(Arends et al 2016).  
Nonsense, frameshift, consensus splice site and certain missense mutations encode for 0 to 
3% residual α-Gal A activity and cause the classic phenotype in males. Alternative splicing 
mutations and certain other missense mutations encode for > 3% of mean normal α-Gal A 
activity and cause late-onset phenotype in males. Considering novel missense mutations, the 
phenotype was classified based on the age of symptoms onset and the type of clinical 
manifestations in males and by in vitro expression assays (Yasuda et al 2003; Benjamin et al 
2017). The phenotype was assigned on a family basis; the assignment is shown in 
Supplementary Table 1. These assignments are supported by previous clinical and 
biochemical studies reported in the Human Gene Mutation Database (HGMD) (Stenson et al 
2017) and the International Fabry Disease Genotype/Phenotype Database (www.dbFGP.org). 
Pathogenic mutations were assigned as amenable or non-amenable to migalastat treatment 
based on the amenability table http://www.galafoldamenabilitytable.com/hcp provided by 
Amicus Therapeutics. This database was created using results of a pharmacogenic cell-based 
assay in cultured HEK-293 cells to identify mutant forms of α-Gal A responsive to migalastat 
(Wu et al 2011; Germain et al 2016). A mutation is defined as amenable to migalastat if the α-
Gal A activity increases to ≥1.20-fold over baseline with an absolute increase of ≥3.0% wild-
type α-Gal A activity in the presence of 10 µmol/l migalastat (Benjamin et al 2017). The 
values of absolute and relative in-vitro increases of α-Gal A activities for the amenable 
mutations included in this study were drawn from the recent publication by Benjamin et al 
(Benjamin et al 2017).  
Statistical analysis 
We used descriptive statistics for demographics and genotype/phenotype information. 
Categorical variables were expressed as proportions, continuous variables as medians with 












ranges. Comparisons between the study groups were performed using Mann–Whitney U test 
and the Chi-square test as appropriate. A multiple line of α-Gal A activity by months of 
measurement was constructed for each migalastat patient. A bivariate correlation between the 
relative increase of the -Gal A activities and the residual -Gal A activities was calculated in 
the peripheral leucocytes of patients and in HEK-cells, the latter as previously published 
(Benjamin et al 2017). A bivariate correlation between the change of lyso-Gb3 levels, 
determined in DBS, and the relative increase of -Gal A activities on migalastat in leucocytes 
was calculated. 
The statistical analyses were performed using the SPSS/PC (version 25.0; SPSS Inc., 
Chicago, IL, USA) software package. All statistical tests were two-sided, and P values < 0.05 
were considered significant.  













Overall, 170 patients from 46 families (n=64 males and 106 females) with 39 different 
mutations were diagnosed during the last 59 years in Switzerland. The demographic, survival 
and biochemical information of the patients, according to phenotype, is summarized in Table 
1. Detailed information on genotype, phenotype, demographics and ongoing specific 
treatment for each Fabry family is displayed in Supplementary Table 1.The -Gal A activity 
of all males with late-onset phenotype is shown in Supplementary Table 2. 
There were considerably more classic than late-onset phenotype patients (129 vs 41; 68%) 
diagnosed in Switzerland.  Classic phenotype patients included 82 females (47% of the 
cohort) and 47 males (29%) (Supplementary Figure 1 A). Classic phenotype males were 
significantly younger than late-onset males (mean age: 39 vs 51 years, p=0.02). Females of 
both groups had a similar age (40 vs 39 years, p=0.37, based on last examination). 
In the whole cohort, 84 patients (48%) had amenable mutations, including 43 (25%) patients 
with classic phenotype (Supplementary Figure 1B). One third of the classic Fabry patients had 
an amenable mutation (Table 1).  
All 41 patients with late-onset phenotype had amenable missense mutations.  
Overall, 11 different mutations were amenable, 4 encoding for the classic and 7 for the late-
onset phenotype (Figure 1). Published data showed that after incubation with migalastat, in 
vitro -Gal A activity of the Swiss amenable mutations was 3.7 to 114.8 % of mean wild type 
(control), corresponding to an absolute increase of enzyme activity level between 3.7 and 
59.3% (Benjamin et al 2017). 
At present, 9 (5 males and 4 females) of the 76 follow-up patients (12%; 3 with classic and 6 
with late-onset phenotype) with amenable mutations are treated with migalastat (Table 2).   












The development of the α-gal A activity in leucocytes of each patient under migalastat 
treatment is shown in Figure 2.   
Migalastat was stopped in 2/11 (18%) patients. A classic male carrying mutation p.S276N had 
been switched back from migalastat to ERT because of the lyso-Gb3 increase. In another male 
carrying the benign variant p.R118C, migalastat was initiated because of vertigo and hearing 
loss which, at this time, were assumed to be Fabry-related, while no other Fabry-related 
manifestations were present in the patient. However, migalastat was stopped after 1.5 years of 
treatment due to lack of improvement.  
In the leucocytes of our patients, the medians of the achieved α-Gal A activities under 
migalastat treatment correlated with their residual α-Gal A activities: 0.68, 0.04 
(Supplementary Figure 2). When analyzing previously published data (Benjamin et al 2017), 
we remarked that the proportional increase of α-Gal A activities in HEK-Cells after 
incubation with migalastat in all amenable mutations of this cohort correlated with the 
residual α-Gal A activities: R=0.94, P<0.001 (Supplementary Figure 3). Overall, 41 
determinations of α-Gal A activities in leucocytes were available in the 11 patients, with 1-7 
determinations in each patient.   
 
Lyso-Gb3 level changes, measured in DBS 6-18 months after migalastat treatment initiation, 
did not correlate with the increase in enzyme activities in the leucocytes in patients on 
migalastat (R=0.05, P=0.91). In patients switched from ERT to migalastat, lyso-Gb3 levels 
rather increased, particularly in the classic male with mutation p.S276N (Table 2).  In 
contrast, in the late-onset male with mutation p.S238N who was naïve to treatment, lyso-Gb3 
level greatly decreased (Table 2). 
 












During the last 59 years in Switzerland, classic families were identified significantly earlier 
compared to the late-onset families, (P<0.001, Table 1, Figure 2).  
In the last 10 years, 33 of 40 Fabry patients (83%) diagnosed in Switzerland had a late-onset 
phenotype, suspected in the index cases on the basis of an unexplained cardiac hypertrophy 
(Figure 3). Subsequently, a cascade screening of their family members was performed.   













This study investigated the phenotypic, genetic and enzyme amenability spectrum of 39 
different GLA pathogenic mutations identified in 170 patients from 46 independent pedigrees 
diagnosed during the last 59 years in Switzerland.  All patients were diagnosed based on 
clinical events or FD-related symptoms and/or after a family screening; all have been 
confirmed as having a pathogenic GLA mutation, as shown in Supplementary Table 1. Almost 
half the patients (n=84; 48%) in the Swiss cohort had amenable mutations. Among those, 33% 
of the classic and 100% of the late-onset phenotype patients had missense mutations fulfilling 
the current amenability criteria for therapy with migalastat. Interestingly, the amenability 
degree varied: the higher the residual -Gal A activity in the leucocytes, the higher the degree 
of amenability in the treated patients. Along the same lines, the published data using HEK-
cells in vitro assay showed that -Gal A activity before incubation with migalastat correlated 
with -Gal A activity achieved with migalastat incubation (Benjamin et al 2017).  
Our study also shows that most late-onset phenotype patients were diagnosed during the last 
10 years. This result is most likely due to increasing disease awareness among cardiologists. 
Despite the fact that the majority (68%) of all diagnosed patients in the Swiss cohort had a 
classic phenotype in males, an increasing number of diagnosed patients (83% during the last 
10 years) had a late-onset phenotype, outlining a paradigm change in diagnosis of the disease 
in recent times. This trend suggests that an even greater proportion of patients with amenable 
mutations currently remains undiagnosed and may become part of the Fabry community in the 
future. This consideration is supported by the fact that incidence of FD late-onset phenotype 
in Europe is 8-20 fold as frequent as incidence of classic phenotype, as shown in the newborn 
screening studies (Spada et al 2006; Burlina et al 2018).  
Only 12% of Fabry patients with amenable mutations are actually treated with migalastat. 
These patients had classic or late-onset phenotype. While all males with pathogenic GLA 
mutations are treated in Switzerland, asymptomatic female patients with classic or late-onset 












phenotype are untreated but have an annual follow-up. Some male and female patients with 
amenable mutations have been treated with ERT for several years. Due to a stable disease 
course under ERT, these patients or their treating physicians have chosen not to switch to 
migalastat.  
Two previous studies estimated the proportion of amenable mutations in the databases 
containing different disease-causing mutations derived from FD patients who participated in 
phase I-III migalastat studies (Germain et al 2012; Giugliani et al 2013; Germain et al 2016). 
In one of these studies, Wu et al found significant concentration-dependent increases in α-Gal 
A activity in response to migalastat in 60% (49 of 81) of the mutations included in the 
database. Similarly, in the other study, Benjamin et al demonstrated that 45% (268 of 600) of 
mutations showed an increase in α-Gal A activities, fulfilling the amenability criteria 
(Benjamin et al 2017). However, the actual proportion of patients who can be considered for 
migalastat therapy is important: in contrast to a mutation database, a community of Fabry 
patients consists of families rather than of single mutations, and the cohort composition 
depends on the diagnostic approaches within a country, such as national screening programs 
and programs increasing physicians’ awareness of the disease. In a study of the Fabry centre 
in Würzburg (Germany), Muntze et al mentioned that 37% of their FD patients had amenable 
mutations (Muntze et al 2018), which is less than in the present Swiss Fabry cohort.  
However, clinical experience with migalastat is too short to predict its potential for long-term 
benefits in patients with amenable mutations. The amenable mutation p. S345P, identified in a 
family of 14 members in our cohort, results into an absolute activity with migalastat of 3.7% 
of wild type in the in vitro assay. Despite the fact that the enzymatic increase satisfied the 
definition of amenability, it is doubtful that the increase in enzyme activity is clinically 
beneficial.  












The minimal α-Gal A activity required to avoid FD has been considered to be 30-35% of 
mean control (Monserrat et al 2007; Chien et al 2012; Schiffmann et al 2016). However, to 
define amenability for a certain mutation, we currently can only use the expression results in 
HEK 293 cells. It is unclear to what extent the α-Gal A activity in HEK 293 cells correlate 
with the in vivo activities in PL of affected Fabry males. For instance, mutation S238N in our 
cohort has been shown to express 37% of mean control in HEK-cells without migalastat 
(Benjamin et al 2017); this value exceeds the mentioned pathogenic threshold of 30-35%. 
However, all three males with this mutation clearly have FD, and their α-Gal A activity was 
below 10% of mean controls in the leucocytes, as shown in Table 2. Similarly, enzyme 
activity of the M290I variant expressed in HEK-cells is 68% of mean controls (Benjamin et al 
2017), but has been shown to be clinically associated with FD (Shabbeer et al 2006).  
The fact that α-Gal A activity in vivo and in HEK 293 cells can differ illustrates the 
importance of enzyme testing in both, in vitro and in vivo, at baseline and on migalastat. 
Importantly, the increase of α-Gal A activities in the leucocytes of our patients correlated with 
the residual activity, suggesting that (i) patients with higher residual activity derive more 
benefit from migalastat treatment and (ii) the determinations of α-Gal A activity, before and 
on migalastat should be introduced as standard and used as part of the clinical amenability 
definition and as a way to follow patients on migalastat. Interestingly, enzyme activity in the 
patient with the benign variant R118C also increased under migalastat. Nevertheless, 
migalastat therapy was stopped after 1.5 years of treatment due to the lack of improvement for 
symptoms initially assumed to be FD-related (vertigo, hearing loss). Consequently, patients 
with benign non disease-causing variants should not be treated, although their mutations 
fulfill the amenability criteria.   
 In the treatment naïve male with late-onset phenotype, lyso-Gb3 decreased along with the 
increasing α-Gal A activity. In contrast, in the treatment naïve female with the classic 
phenotype, lyso-Gb3 slightly increased despite an α-Gal A activity increase. In patients 












switched from ERT to migalastat, lyso-Gb3 tended to increase, particularly in a male with 
classic phenotype. In patients on ERT, it is not surprising that the change in endogenous 
enzyme activity does not correlate with change in lyso-Gb3, as they were treated with 
exogenous enzyme. An increasing level of lyso-Gb3 after switch to migalastat has already 
been observed in a recent article by Muntze et al (Muntze et al 2018). These findings suggest 
that migalastat cannot stabilize important biomarkers in all patients; the clinical impact of this 
result needs to be further studied.  
 
Appropriate biomarkers for migalastat therapy monitoring need to be developed.   
Importantly, the classic and the late-onset phenotype represent two different entities requiring 
different diagnostic and therapeutic strategies. The symptomatic classic phenotype can be 
clinically suspected and diagnosed early. In contrast, the late-onset phenotype usually remains 




 decade, due to significant residual -Gal A activity. Adult 
males present relatively early with hypertrophic cardiomyopathy or with chronic kidney 
disease, often at an advanced stage because of the silent disease progression (von Scheidt et al 
1991; Nakao et al 1995; Nakao et al 2003; Shabbeer et al 2006). Thus, for the initially subtle 
late-onset phenotype, screening programs in risk populations (Doheny et al 2018) with 
subsequent cascade family screening may help decrease the number of undiagnosed patients.  
 
The strength of this study is that the phenotypic and amenability composition of the Swiss 
cohort resulted from the study of a real-life population over a significant 59 year period at 
multiple centers. Due to Swiss regulations, all adult patients ever diagnosed and treated with 
FD in Switzerland were registered at the three specialized centres and ERT prescriptions and 
patient follow-up were preserved at the Fabry centres. This study is limited by the relatively 
small number of families affected by this rare disease. Additionally, we cannot report long-












term clinical treatment experience with migalastat and we also cannot, so far, systematically 
correlate the α-Gal A activities in the HEK 293 cell assay with that of leucocytes in a large 
number of males with amenable mutations on migalastat treatment. 
In conclusion, patients with both classic and late-onset phenotypes can have amenable 
mutations. In a national cohort where no systematic screening program has been conducted 
most patients have classic phenotype, and almost half the patients in the entire cohort have 
amenable mutations. However, further studies are required to investigate the long-term 
benefits of migalastat therapy depending on the achieved enzyme activity of different 
amenable mutations.   
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Table 1. Summary of demographic, survival and biochemical information of all Swiss Fabry patients according to phenotype. 
 Classic Phenotype, (129 
patients) 
Late-Onset Phenotype, (41 
patients) 
P-value 
Number of different mutations 32 7  
Number of families 34 12  
  Number of alive males, n (%) 33 (26) 15 (37)  
  Number of alive females, n (%) 71 (55) 22 (54)  
  Number of deceased males, n (%)  14 (11) 0 (0)  
  Number of deceased females, n (%)  10 (7.8) 1 (2.4)  
Age in years, median (range):    
  alive males  39 (19-71) 51 (24-72) 0.02 
  alive females 40 (17-79) 39 (17-77) 0.37 
  deceased males 57 (40-76) n.a. n.a. 
  deceased females 66 (36-84) 51 (51-51) 0.30 
Year of diagnosis, median (range) 2004 (1960-2019) 2012 (1995-2019) <0.001 
Number of patients with amenable mutations, n 43 (33) 41 (100)  













Type of  mutations:    
  Missense, n (%) 71 (55) 37 (100)  
  Deletions, n (%) 26 (20) 0 (0)  
  Duplications, n (%) 17 (13) 0 (0)  
  Nonsense, n (%) 10 (7.8) 0 (0)  
  Consensus Splice Site, n (%) 8 (6.2) 0 (0)  
 
 










Leucocytes α-gal A 
activity, % of controls   
α-Gal A Activity in HEK-
cells , % of wild type    
 
LysoGb3 levels in DBS, ng/mL 
(reference<3.5 ng/mL) 







Males          
c.827G>A, 
p.S276N 
Classic 42 α-agalsidase 3.0 9.9 [8.9-10.6] 2.3 9.3 27 109 (18) 














Late-Onset 60 - 9.2 33 18 41   
c.644A>G, 
p.N215S 
Late-Onset 67 α-agalsidase BLD‡ 45 [30-62] 16 36 3.6 4.7 (18) 
c.713G>A,  
S238N 
Late-Onset 63 - 6.8 30 37 96 13 5.6 (7) 
c.713G>A, 
p.S238N 
Late-Onset 58 α-agalsidase 4.0 24 37 96  8.0 (18) 
c.713G>A, 
p.S238N 
Late-Onset 56 α-agalsidase 9.0 25 37 96  7.0 (13) 
Females          
c.125T>C,  
p.M42T  
Classic 29 α-agalsidase 25 34 2.5 20 6.3 5.9 (3) 
c.581C>T,  
p.T194I 
Classic 60 α-agalsidase 7.2 8.9 [4.3-15.5] 2.3 
 
19 7.9 8.2 (12) 
c.1033T>C, 
p.S345P 
Classic 33 - 25 71 [70-103] BLD 3.7 5.3 6.7 (17) 
c.902G>A, 
p.R301Q 
Late-Onset 71 α-agalsidase 61 127 [112-
167] 
5.5 45 3.6 3.6 (6) 
Abbreviations: ERT, enzyme replacement therapy; DBS, dried blood spots; BLD, below the limit of detection. 
*if available; for leucocytes α-gal A activity, median and interquartile range was calculated if >2 measurements were available. 
†
measured 6-18 months after migalastat initiation. 
‡this result has been repeatedly confirmed and validated by normal enzymatic activity of β-Glucuronidase.














Figure 1. Effect of Migalastat on the α-Gal A activities Measured in HEK-293 Cell Lysates 
with Classic (red) and Late-Onset (green) mutations which meet the amenability criteria.   
 
Figure 2. Figure 2. Development of the α-Gal A activities in the peripheral leucocytes for 
each male and female under migalastat treatment. Dotted line represents the non-disease 
causing variant R118C. 
  
Figure 3. Number of Patients with Classic and Late-Onset Phenotype mutations diagnosed per 
year.   
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